Oramed Pharmaceuticals Files 8-K with Material Agreement
Ticker: ORMP · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-filings
TL;DR
Oramed filed an 8-K on Feb 28, 2025, reporting a material definitive agreement and financial filings.
AI Summary
On February 28, 2025, Oramed Pharmaceuticals Inc. entered into a material definitive agreement. The company also filed financial statements and exhibits as part of this 8-K filing. The exact nature of the agreement and the details of the financial statements are not specified in the provided text.
Why It Matters
This filing indicates a significant development for Oramed Pharmaceuticals, potentially involving new partnerships, acquisitions, or financial restructuring that could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks, and the lack of specific details in the filing necessitates caution.
Key Players & Entities
- ORAMED PHARMACEUTICALS INC. (company) — Registrant
- February 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-35813 (identifier) — Commission File Number
- 98-0376008 (identifier) — IRS Employer Identification No.
FAQ
What is the specific nature of the material definitive agreement entered into by Oramed Pharmaceuticals?
The provided text states that Oramed Pharmaceuticals Inc. entered into a material definitive agreement on February 28, 2025, but does not specify the details of this agreement.
What financial statements and exhibits were filed with this 8-K?
The filing indicates that financial statements and exhibits were included, but the specific content or nature of these documents is not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 28, 2025.
In which U.S. state is Oramed Pharmaceuticals Inc. incorporated?
Oramed Pharmaceuticals Inc. is incorporated in Delaware.
What is Oramed Pharmaceuticals Inc.'s Commission File Number?
Oramed Pharmaceuticals Inc.'s Commission File Number is 001-35813.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding ORAMED PHARMACEUTICALS INC. (ORMP).